
Opinion|Videos|November 8, 2024
Considerations for Use of CAR T-cell Therapy in Multiple Myeloma
Panelists discuss how patient and disease factors influence the choice between ide-cel and cilta-cel for chimeric antigen receptor (CAR) T-cell therapy, the significance of adverse event profiles in clinical decision-making, the use of bridging therapy prior to infusion, and the experiences of progression rates and potential mechanisms post treatment, as well as future directions for CAR T-cell therapy in relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series

- Dr Ajai Chari to Dr Rossi (then open to panelists): What patient or disease factors do you weigh when deciding whether a patient should receive ide-cel vs cilta-cel?
- Dr Ajai Chari to Dr Martin: When weighing treatment options, how heavily is the chimeric antigen receptor (CAR) T adverse effect (AE) profile considered in your clinical judgment?
- What are the similarities and differences between the AE profiles of ide-cel vs cilta-cel?
- Dr Ajai Chari to Dr Callander: What is your approach to bridging therapy prior to CAR T-cells being infused?
- How frequently do you utilize bridging therapy? What agents are you typically using?
- Dr Ajai Chari to Dr Raje: Of the patients you have treated with CAR T-cell therapy, what percentage of patients have progressed?
- How long until progression occurs in your experience?
- What are some possible mechanisms of release post CAR T-cell therapy?
- Dr Ajai Chari to Dr Rossi: What are some future directions for CAR T-cell therapy in relapsed/refractory multiple myeloma?
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
FDA Issues CRL to Ivonescimab Plus Chemo for Locally Advanced or Metastatic NSCLC
5

